AxoGen (NASDAQ:AXGN) Director Sells $640,995.00 in Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Kathy Johnson Weiler sold 14,150 shares of AxoGen stock in a transaction on Friday, August 7th. The stock was sold at an average price of $45.30, for a total transaction of $640,995.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AxoGen Stock Performance

AxoGen stock opened at $48.05 on Friday. The firm has a fifty day simple moving average of $43.31 and a two-hundred day simple moving average of $38.37. The company has a quick ratio of 5.04, a current ratio of 6.60 and a debt-to-equity ratio of 0.07. AxoGen, Inc. has a twelve month low of $13.64 and a twelve month high of $49.93. The company has a market capitalization of $2.58 billion, a PE ratio of -70.66 and a beta of 1.11.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.12. The firm had revenue of $69.73 million for the quarter, compared to analysts’ expectations of $67.10 million. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. Research analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on AXGN shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $48.00 price target on shares of AxoGen in a research note on Wednesday, April 29th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th. Citizens Jmp upped their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Thursday, July 30th. Citigroup reissued a “market outperform” rating on shares of AxoGen in a research report on Thursday, July 30th. Finally, HC Wainwright raised their price target on shares of AxoGen from $50.00 to $53.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Institutional Investors Weigh In On AxoGen

A number of large investors have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of AxoGen during the second quarter valued at approximately $3,100,000. Globeflex Capital L P purchased a new stake in AxoGen in the second quarter worth $2,702,000. B. Metzler seel. Sohn & Co. AG purchased a new stake in AxoGen in the second quarter worth $3,746,000. Edmond DE Rothschild Holding S.A. bought a new stake in AxoGen in the second quarter valued at $1,469,000. Finally, Lisanti Capital Growth LLC bought a new stake in AxoGen in the second quarter valued at $4,183,000. 80.29% of the stock is currently owned by institutional investors.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.